跳到正文
原文
Endpoints News 生物医药· Ayisha Sharma·· 2026-10-20AI 评分42

Rapport Therapeutics 表示其从 J&J 获得许可的 AMPA 受体调节剂通过双相型躁狂症 II 期试验

Rapport says drug it licensed from J&J clears Phase 2 bipolar mania study

AI 导读

Rapport Therapeutics 称其从 J&J 获得许可的 investigational 口服 AMPA 受体调节剂在双相型躁狂症中期试验(Phase 2)中达到终点。

正文

Rap­port Ther­a­peu­tics said Tues­day its in­ves­ti­ga­tion­al oral drug that di­als down the ef­fect of AM­PA re­cep­tors has cleared a mid-stage tri­al in bipo­lar ma­nia, paving …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news